Prestwick Pharmaceuticals Inc, whose drug products target chronic diseases of the central nervous system, said on Friday it is seeking to go public in an initial stock offering. The Washington, D.C.-based company, in a preliminary offering document filed with the US Securities and Exchange Commission, said it is seeking to raise as much as $74.75 million from the sale of common stock. It did not, however, provide the number of shares or the price per share as those details are customarily disclosed in future filings.
The underwriters are UBS Investment Bank, Deutsche Bank Securities and CIBC World Markets.
The company said it plans to apply for a Nasdaq listing under the symbol "PWCK.